NCT05526443unknownrecruiting

Austrian Registry for Evaluation of Treatment Patterns and Outcome in Patients With Advanced Pancreatic Ductal Adenocarcinoma (PDAC)

Medical University of Graz

ClinicalTrials.gov

1500

Enrollment · estimated

Countries · 14 sites

2027-12

Primary completion

8 days ago

Record updated

Commercial relevance

Trial record references NGS / genomic profiling referenced.

NGS / genomic profiling

Biomarker requirement language

Diagnosis of histologically confirmed locally advanced inoperable and/or metastatic PDAC
Signed informed consent for prospective patients, for retrospective cases no informed consent is required

Change timeline

No changes detected yet. The first refresh records a baseline snapshot; subsequent refreshes generate field-level changes.

Signals from this trial

New trial
45/100
Opportunity
New unknown trial NCT05526443 posted by Medical University of Graz: "Austrian Registry for Evaluation of Treatment Patterns and Outcome in Patients With Advanced Pancreatic Ductal Adenocarcinoma (PDAC)".
ClinicalTrials.gov record updated 7 days ago.

Eligibility — raw, for validation

Inclusion Criteria:

* 18 years, female and male
* ECOG (Eastern Cooperative Oncology Group) Scale 0-2
* Diagnosis of histologically confirmed locally advanced inoperable and/or metastatic PDAC
* Patients undergoing palliative 1st line therapy with a platinum- or gemcitabine- based chemotherapy in case of previous (neo)adjuvant therapy also patients who receive nal-Irinotecan/5-FU/Leukovorin as palliative first line are eglible
* Signed informed consent for prospective patients, for retrospective cases no informed consent is required

Exclusion Criteria:

* Patients with locally advanced operable PDAC who do not receive palliative chemotherapy
* Patients with locally advanced borderline resectable PDAC who do not receive palliative chemotherapy